9 Best Rising Penny Stocks to Buy According to Wall Street Analysts

7. ​Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

One Month Performance: 14.72%

Number of Hedge Fund Holders: 26

Analyst Upside Potential: 38.01%

​Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has gained more than 14.72% over the past month, and Wall Street expects more than 38% upside from the current level. The stock also ranks as one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts.

​Much of the gains are driven by healthy momentum from fiscal Q1 2026 earnings released last month on May 7. During the quarter, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) reported $106.51 million in revenue and topped the expectations of $92.1 million. The growth was driven by a 97% year-over-year increase in the US LINZESS net sales, which reached $272.5 million. Management noted that the drug sales improved due to a strategic 50% list price reduction that eliminated costly inflationary rebates and boosted net pricing.

​Investors remain concerned regarding the company’s heavy reliance on LINZESS. On the bright side, the company remains on track to initiate the confirmatory Phase 3 STARS-2 clinical trial for Apraglutide in the second quarter of 2026. Moreover, management reiterated its 2026 outlook, projecting total revenue between $450 million and $475 million and adjusted EBITDA exceeding $300 million.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a biopharmaceutical company focused on developing and commercializing transformative therapies for gastrointestinal (GI) and rare diseases.